RecruitingPhase 1NCT07008118

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

A Phase 1, Open-Label, Multicenter Study of INCA035784 in Participants With Myeloproliferative Neoplasms

Sponsor

Incyte Corporation

Enrollment

120 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

Myeloproliferative Neoplasms

Summary

This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called INCA035784 for people with myeloproliferative neoplasms. The study is currently recruiting participants at 27 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGINCA035784

INCA035784 will be administered at the assigned dose in the dose escalation part and at the protocol defined dose in the dose expansion part.

Locations(26)

Mayo Clinic Hospital

Phoenix, Arizona, United States

Stanford University

Palo Alto, California, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Mayo Clinic-Florida

Jacksonville, Florida, United States

University of Chicago Medical Center

Chicago, Illinois, United States

Johns Hopkins University

Baltimore, Maryland, United States

Icahn School of Medicine At Mount Sinai

New York, New York, United States

University of North Carolina At Chapel Hill

Chapel Hill, North Carolina, United States

South Austin Medical Center

Austin, Texas, United States

University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center Blood

Dallas, Texas, United States

Huntsman Cancer Institute At University of Utah

Salt Lake City, Utah, United States

Medical College of Wisconsin

Milwaukee, Wisconsin, United States

Macquarie University Hospital

Sydney, New South Wales, Australia

Royal Adelaide Hospital

Adelaide, South Australia, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Linear Clinical Research

Nedlands, Western Australia, Australia

Cliniques Universitaires Saint-Luc

Brussels, Belgium

Universitair Ziekenhuis Gent

Ghent, Belgium

Universitaire Ziekenhuizen Leuven

Leuven, Belgium

Universitaetsklinikum Dresden

Dresden, Germany

Universitatsklinikum Halle (Saale)

Halle, Germany

Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii

Mainz, Germany

Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii

Bergamo, Italy

Azienda Ospedaliero Universitaria Careggi-S.O.D. Patologia Medica

Florence, Italy

Fondazione Irccs Ca Granda Ospedale Maggiore

Milan, Italy

Centro Ricerche Cliniche Di Verona

Verona, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07008118

Related Trials

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

NCT0744169454 locations

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT033149741 location

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

NCT0631359330 locations

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0603400213 locations

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

NCT0593635929 locations